Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 506

Results For "IT"

11179 News Found

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
News | March 25, 2026

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'

New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis


Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Biotech | March 25, 2026

Earendil Labs bags $787m to supercharge AI-driven biologics pipeline

Capital infusion to accelerate Earendil’s R&D platform


Japan okays new long-acting eye drug
News | March 24, 2026

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients


Bayer wins world-first nod in Japan for low-dose MRI contrast agent
News | March 24, 2026

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging


Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
Clinical Trials | March 24, 2026

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

The company plans to submit the vaccine for regulatory review


Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
Clinical Trials | March 24, 2026

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials


Zydus launches affordable Semaglutide in India after patent expiry
News | March 23, 2026

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders


Godavari Biorefineries secures Japanese patent for antiviral compounds
R&D | March 23, 2026

Godavari Biorefineries secures Japanese patent for antiviral compounds

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways


TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
News | March 23, 2026

TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial

The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611